.jpg?format=webp&quality=80&width=3840)
Although systemic embolism is a potential complication in transthyretin amyloid cardiomyopathy (ATTR‐CM), data about its incidence and prevalence are scarce. The authors studied the incidence, prevalence and factors associated with embolic events in ATTR‐CM. Additionally, the study evaluated embolic events according to the type of oral anticoagulation (OAC) and the performance of the CHA2DS2‐VASc score in this setting. The CHA2DS2‐VASc score did not correlate well with clinical outcome in ATTR‐CM and should not be used to assess thromboembolic risk in this population.
Like
Save
Share